Company news
Passage Bio, Inc. (NASDAQ:PASG) news
Every Passage Bio, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Passage Bio and Remix Therapeutics Announce Merger Agreement
June 25, 2026
Passage Bio and Remix Therapeutics Announce Merger Agreement
June 24, 2026
Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates
April 20, 2026
Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights
March 3, 2026
Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights
November 10, 2025
Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference
November 5, 2025
Passage Bio to Participate in Chardan’s 9th Annual Genetic Medicines Conference
October 14, 2025
Passage Bio to Participate in H.C. Wainwright 27th Annual Global Investment Conference
August 28, 2025
Passage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business Highlights
August 12, 2025
Passage Bio Announces 1-for-20 Reverse Stock Split
July 10, 2025
Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update
June 23, 2025
Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights
May 13, 2025
Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights
March 4, 2025
Passage Bio to Participate in Upcoming Investor Conferences
February 26, 2025
Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates
January 10, 2025
Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights
November 13, 2024
Passage Bio to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in upliFT-D Study at 14th International Conference on Fr...
September 16, 2024
Passage Bio Welcomes Tom Kassberg to Board of Directors
September 10, 2024
Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights
August 8, 2024
Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration
August 1, 2024
Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients
July 16, 2024
Passage Bio Announces Recipient of Third Annual Tachi Yamada Scholarship Award
May 21, 2024
Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
May 14, 2024
Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights
March 4, 2024
Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities
December 20, 2023
Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
November 17, 2023
Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights
November 13, 2023
Passage Bio Announces Promising Interim Clinical Data from First Eight Patients with GM1 Gangliosidosis in Imagine-1 Study
August 7, 2023
Passage Bio Welcomes Dolan Sondhi, Ph.D. to Board Of Directors
July 31, 2023
Passage Bio to Present at Goldman Sachs 44th Annual Global Healthcare Conference
June 5, 2023
Passage Bio Reports First Quarter 2023 Financial Results and Provides Recent Business Highlights
May 11, 2023
Passage Bio Announces Recipient of Second Annual Tachi Yamada Scholarship Award
May 4, 2023
Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 21, 2023
Passage Bio to Present at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
April 17, 2023
Passage Bio to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days
March 27, 2023
Passage Bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Recent Business Highlights
March 6, 2023
Passage Bio Seeks Pennsylvania College Student Candidates for Second Annual Tachi Yamada Scholarship Program
March 1, 2023
Passage Bio to Present at Cowen 43rd Annual Health Care Conference
February 28, 2023
Passage Bio to Report Fourth Quarter and Full-Year 2022 Financial Results on March 6, 2023
February 27, 2023
Passage Bio Presents Additional Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium™ 2023
February 24, 2023
Passage Bio to Present Updated Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium™ 2023
February 15, 2023
Passage Bio Announces Positive Interim Clinical Data from First Six Patients with GM1 Gangliosidosis in Imagine-1 Study
December 14, 2022
Passage Bio Reports Third Quarter 2022 Financial Results and Provides Business Updates
November 10, 2022
Passage Bio to Present at Guggenheim 4th Annual Immunology & Neurology Day
November 8, 2022
Passage Bio to Report Third Quarter 2022 Financial Results on November 10, 2022
November 3, 2022
Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 14, 2022
Passage Bio Announces Appointment of William Chou, M.D. as Chief Executive Officer
October 10, 2022
Passage Bio to Present at Chardan’s 6th Annual Genetic Medicines Conference
September 26, 2022
Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
August 19, 2022
Passage Bio Doses First Patient in Global Clinical Trial of PBFT02 Gene Therapy for Frontotemporal Dementia with Granulin Mutations
August 11, 2022